| Description |
1 online resource (277 p.) |
| Series |
Frontiers in Anti-Infective Drug Discovery Ser |
|
Frontiers in Anti-Infective Drug Discovery Ser
|
| Contents |
Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- Eradication of Helicobacter pylori Infection with Non-Bismuth Quadruple Concomitant Therapy -- Javier P. Gisbert* and Adrian G. McNicholl -- INTRODUCTION -- OBJECTIVE -- BIBLIOGRAPHICAL SEARCHES -- EFFICACY OF THE CONCOMITANT REGIMEN -- COMPARISON BETWEEN CONCOMITANT AND STANDARD TRIPLE REGIMEN -- COMPARISON BETWEEN CONCOMITANT AND SEQUENTIAL REGIMENS -- EFFECTS OF DIFFERENT VARIABLES ON THE EFFICACY OF CONCOMITANT THERAPY -- Clarithromycin Resistance -- Nitroimidazole Resistance |
|
Dual Clarithromycin and Metronidazole Resistance -- Duration of Treatment -- HOW COULD WE EVEN INCREASE THE EFFICACY OF THE CONCOMITANT TREATMENT? -- WHAT ARE THE RESULTS WITH THE CONCOMITANT TREATMENT IN CLINICAL PRACTICE? THE EXPERIENCE OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT -- CONCLUSIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Drug Discovery Strategies Against Emerging Coronaviruses: A Global Threat |
|
Paulo Fernando da Silva Santos-Júnior1, Igor José dos Santos Nascimento1, Thiago Mendonça de Aquino1, João Xavier de Araújo-Júnior2 and Edeildo Ferreira da Silva-Júnior1,2,* -- INTRODUCTION -- BIOLOGICAL ASPECTS, SIGNS/SYMPTOMS AND DIAGNOSIS FOR MERS-COV, SARS-COV, AND SARS-COV-2 -- STRATEGIES USED FOR DISCOVERING NEW POTENTIAL DRUGS -- Natural Source -- Classical Methods Applied for Discovering New Antiviral Agents -- Virtual Screening and Computational Techniques for Designing New Antiviral Agents -- Drug Repurposing -- High-Throughput Screening (HTS) for Discovering New Antiviral Agents |
|
Case Study 4: Mycobacterium Tuberculosis (Mtb) -- Pantothenate Synthetase (PanC) -- Mtb Transcriptional Repressor (EthR) -- Mycocyclosin Synthase (CYP121) -- Fructose 1,6-bisphosphate Aldolase (FBA) -- RECENT ADVANCES IN FBDD -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Phage Therapy as a Tool for Control of Foodborne Diseases: Advantages and Limitations -- S. Pacios-Michelena1,2, R. Rodríguez-Herrera1, A. C. Flores-Gallegos1, M.L Chávez González2, E.P. Segura-Ceniceros2, R. Ramos-González3 and A. Ilyina2,* -- INTRODUCTION -- BACTERIOPHAGE |
| Summary |
This book series brings updated reviews to readers interested in advances in the development of anti-infective drug design and discovery. The scope of the book series covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for dev |
| Notes |
Description based upon print version of record |
| Subject |
Anti-infective agents.
|
|
Communicable diseases.
|
|
Anti-Infective Agents
|
|
Communicable Diseases
|
|
Anti-infective agents
|
|
Communicable diseases
|
| Form |
Electronic book
|
| Author |
Choudhary, M. Iqbal
|
| ISBN |
9811412383 |
|
9789811412387 |
|
